OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
OS Therapies Inc., a clinical-stage biopharmaceutical company focused on ADC and immunotherapy research, filed this Current Report on Form 8-K on January 10, 2025. The report details the completion of the second closing of a private placement of securities previously announced on December 30, 2024.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1,053,000 from the second closing.
- Securities Issued: 263,250 Units, each consisting of one share of Series A Senior Convertible Preferred Stock and one warrant to purchase one share of common stock.
- Price per Unit: $4.00.
- Transaction Fees: $35,157 paid to placement agent Brookline Capital Markets and $17,552 paid to dealer Ceros Financial Services, Inc.
- Agent Warrants: Issued warrants to purchase 8,788 shares to Brookline and 4,388 shares to Ceros.
- Liquidity and Debt: The filing does not provide updated balance sheet data, total cash balances, or debt levels outside of the new equity issuance.
Material Changes and Agreement Terms
The Company entered into Amendment No. 1 to the Securities Purchase Agreement and Registration Rights Agreement to facilitate additional closings. Key terms of the Series A Preferred Stock include:
- Conversion Triggers: Mandatory conversion occurs upon a qualified public offering or PIPE financing raising over $10 million or $20 million respectively at a price of at least $12.00 per share, a cash acquisition at $12.00 per share, or if the daily VWAP exceeds 300% of the conversion price for 20 consecutive trading days.
- Liquidation Preference: 150% of the original issue price.
- Voting Rights: One vote per share on an as-converted basis, with a voting price floor based on the closing price prior to the Purchase Agreement execution.
- Issuance Restrictions: The Company is restricted from issuing additional common stock or variable rate transactions for six months post-closing or until stockholder approval is obtained, with exceptions for equity lines of credit at prices not less than 300% of the conversion price ($12.00).
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, revenue projections, or management commentary regarding clinical trial timelines. The primary risk highlighted is the dilution and restrictions on future capital raising activities imposed by the Purchase Agreement. The Company is obligated to file a registration statement covering 300% of the underlying shares within 30 days of the second closing and seek effectiveness within 45 days.
Investor Verification Checklist
- Verify the total aggregate gross proceeds raised across all closings of the Private Placement to date.
- Confirm the current cash position and runway of the Company following the $1.053 million inflow.
- Review the full text of the Certificate of Designation (Exhibit 3.1 in prior filing) for specific details on dividend rights and redemption provisions.
- Monitor the status of the Registration Statement filing required within 30 days of January 10, 2025.
- Assess the impact of the 150% liquidation preference on common stockholders in a liquidation scenario.